Description
Oczyesa has been approved by the European Commission for use within the European Union. Specifically, the European Commission granted full marketing authorization for Oczyesa on 30 June 2025, following a positive opinion from the EMA’s CHMP in April 2025.
Oczyesa® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Oczyesa prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Oczyesa 20 mg cost in India, please call/WhatsApp +91-9891296838 or send an email to support@southdelhipharma.com, southdelhipharma@gmail.com
Apart from Gulf countries, Oczyesa® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). South Delhi Pharma can help facilitate the legal supply of Oczyesa® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.
